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Abstract
The development of childhood solid tumours is tied to early developmental processes. These tumours may be
complex and heterogeneous, and elucidating the aberrant mechanisms that alter the early embryonic environment
and lead to disease is essential to our understanding of how these tumours function. MicroRNAs (miRNAs) are vital
regulators of gene expression at all stages of development, and their crosstalk via developmental signalling
pathways is essential for orchestrating regulatory control in processes such as proliferation, differentiation and
apoptosis of cells. Oncogenesis, from aberrant miRNA expression, can occur through amplification and
overexpression of oncogenic miRNAs (oncomiRs), genetic loss of tumour suppressor miRNAs, and global miRNA
reduction from genetic and epigenetic alterations in the components regulating miRNA biogenesis. While few
driver mutations have been identified in many of these types of tumours, abnormal miRNA expression has been
found in a number of childhood solid tumours compared to normal tissue. An exploration of the network of key
developmental pathways and interacting miRNAs may provide insight into the development of childhood solid
malignancies and how key regulators are affected. Here we present a comprehensive introduction to the roles and
implications of miRNAs in normal early development and childhood solid tumours, highlighting several tumours in
depth, including embryonal brain tumours, neuroblastoma, osteosarcoma, Wilms tumour, and hepatoblastoma. In
light of recent literature describing newer classifications and subtyping of tumours based on miRNA profiling, we
discuss commonly identified miRNAs, clusters or families associated with several solid tumours and future directions
for improving therapeutic approaches.
Keywords: MicroRNAs, Early development, Childhood solid tumours, Neuroblastoma, Medulloblastoma,
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Background
MicroRNAs (miRNAs) are a group of small non-coding
RNAs, around 19–22 nucleotides in length, first discov-
ered in nematodes (Caenorhabditis elgans) in 1993 [1].
Now there are thousands of miRNAs identified in many
different eukaryote species [2]. Previously, miRNAs and
other noncoding RNAs were dismissed as transcriptional
noise [3, 4]. However, recently the ENCODE project
revealed that in the human genome there is a vast network
of important interactions that occur between regulatory
elements, primarily composed of transcription factors and
miRNAs [5–7]. miRNAs can regulate gene expression in
several ways, through DNA interaction, translational re-
pression or by directly targeting mRNA degradation, and
they play vital roles in nearly all biological pathways [8].
With this characterization we now know different sets of
miRNAs are expressed in specific cell and tissue types and
therefore they play an important role in shaping cellular
identity [9, 10]. In addition, miRNAs have been shown to
regulate oncogenes, tumour suppressor genes and have an
impact on cell cycle control, apoptosis, cell migration and
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angiogenesis [11–19]. Taken together, these discoveries
provide insight into the importance of the roles of miR-
NAs in maintaining normal cellular function and how dis-
ruptions in miRNA expression profiles may heavily impact
the development, differentiation, and control of growth
leading to diseases such as cancer.
Cancer is a disease of diverse genetic and epigenetic
complexity involving changes in gene expression [20–22].
For a long time, carcinogenesis was largely attributed to
abnormalities in oncogenes and tumour suppressing
genes. It is now widely recognized that miRNAs also play
critical roles in cancer. Aberrant miRNA expression asso-
ciated with cancer development can occur through a
number of different types of mechanisms, each of which is
a critical event that could greatly alter early development
and give rise to the pathogenesis of childhood cancers.
There has been recent work indicating that global
miRNA profiles are able to classify human cancers
tissues, including paediatric solid tumours [23, 24]. An
investigation into biomarkers and risk stratification in
childhood solid tumours highlighted that specific serum
miRNA profiles can be identified in childhood solid tu-
mours. The results supported the proposed use of
miRNA profiling from serum as a non-invasive method
with the potential to diagnose childhood solid tumours
[25]. Also of note is the emerging evidence of disrupted
components of the miRNA biogenesis pathway, which, if
altered, affect miRNA expression levels on a global scale.
Enzymes involved in the production of mature miRNAs
have been implicated in certain childhood cancers, in-
cluding neuroblastomas and Wilms tumour [26–28].
In recent years, the concepts of cell of origin (COO) and
cancer stem cells (CSCs) have gained traction; these con-
cepts are distinct. The COO is a normal cell, which has
acquired the first cancer promoting mutation, and CSCs
are the cellular component of a tumour that maintains
malignant growth. Therefore, COOs and CSCs are cancer
initiating and cancer propagating respectively. Investiga-
tors have identified a number of miRNAs associated with
CSCs, differentially expressed in six paediatric solid
tumour cell lines [29]. The identified potential targets
were further investigated using in silico biological analyt-
ical processes, which revealed four annotated pathways
that were enriched: cell cycle, cell proliferation, p53 and
TGF-beta/BMP. This highlights an important consider-
ation; the actions of miRNAs on key critical developmen-
tal pathways could have major effects on how these
pathways function, and could be deleteriously affected by
deregulated miRNAs, causing a chain of events which
may lead to an environment where cancer develops [30].
The scope of this review aims to address the current
state of miRNA research in relation to childhood solid
tumours. Due to the necessarily precise genetic regula-
tion that occurs during development, it is plausible that
miRNAs play a major role in childhood cancers. A dee-
per understanding of the links between the deregulation
of miRNAs and childhood cancers can improve the way
children are diagnosed and treated. Here we briefly de-
scribe miRNA biogenesis, how miRNAs function in early
development and their ability to act as tumour suppres-
sors and oncomiRs. In addition, the key developmental
pathways and how they lead to malignancies in different
organs is examined through the lens of miRNA action.
We explore several childhood solid tumours in detail,
neuroblastoma, osteosarcoma, nephroblastoma (Wilms
tumour), hepatoblastoma, and several types of brain tu-
mours. In the following discussion of these solid tumour
types, miRNAs (or families) identified as aberrantly
expressed in multiple tumour types are highlighted in an
effort to understand where connections between the de-
velopmental processes and childhood solid tumours
might be used as a basis for discovering shared mecha-
nisms. It remains challenging to interpret how the many
targets of individual miRNAs directly affect downstream
processes, leading to development or progression of
childhood cancer; however, pending accurate interpreta-
tions, this may lead to the discovery of targetable path-
ways and assist in the generation of new therapies.
The miRNA biogenesis process
miRNAs are initially processed from precursor mole-
cules (pri-miRNAs) in the nucleus [31, 32]. Pri-miRNAs
are transcribed by RNA polymerase II/III from independ-
ent genes, or intronic sequences. The pri-miRNAs fold
into hairpins, and are cleaved by the enzymes Drosha and
Dicer in a two-step processing function [33, 34]. First the
nuclear localised complex of DROSHA and DGCR8
cleaves the pri-miRNA, producing a ~70 nucleotide
pre-miRNA. This is exported to the cytoplasm by the
complex Exportin 5-Ran-GTP, where TRBP and
DICER process the pre-miRNA to yield a ~20 bp
miRNA/miRNA* coupled pair [35, 36]. One strand
represents the 5’ miRNA, whereas the other strand
represents the 3’ miRNA. Depending on the specific
miRNA one of the strands is preferentially degraded
over the other more highly expressed miRNA [37].
The preferentially expressed miRNA is incorporated
into the miRNA induced silencing complex (miRISC)
which allows miRNAs to target mRNAs and induce
translational repression or deadenylation, and subse-
quent degradation, leading to rapid silencing of the
targeted mRNA transcript gene product [38–41].
miRNA mediated regulation of the genome and key
developmental pathways
Through evolution, miRNAs and their mechanistic fea-
tures for targeting mRNA have been strongly conserved.
An important class of gene regulatory molecules, they
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are often considered “master regulators” of gene expres-
sion, because a single miRNA can bind to, and conse-
quently impact the expression of a number of different
transcripts. Previous evidence has suggested that the
average miRNA has approximately 100 target sites [42].
At the current time miRTarBase, (an experimentally vali-
dated miRNA target interaction database), states there
are 2,619 known human miRNAs validated to target
12,738 genes [43].
The reason miRNAs can affect multiple targets is due to
the mechanism of action in which the miRNAs base-pair
to their targets, involving flexible complementary pairing
with the mRNA. miRNAs base-pair to their target mRNA
on the 3’-UTR, where there are miRNA recognition ele-
ments (MREs). miRNAs implement the use of a critical re-
gion referred to as the “seed region”, a region on the 5’ end
of the miRNA containing 2–8 nucleotides [44, 45]. Inter-
estingly, asymmetry is commonly observed for matches be-
tween the miRNA and its target. The 5’ end of miRNA
tends to have a greater number of complementary bases
than the 3’ end. A key finding indicates that as few as seven
base pairs of complementarity to the miRNA 5’ end are
sufficient to provide regulation [46]. Additionally, 3’ end
complementarity may serve as a specificity factor, allowing
the possibility of different sites to become differentially reg-
ulated by different miRNA family members. These attri-
butes are necessary in development, where dynamic
protein expression occurs in order to orchestrate a number
of critical actions, such as cell lineage decisions and the
resulting morphogenetic events. If additionally we consider
that there are a surprisingly large number of miRNA target
sites within the genome, it becomes apparent that miRNAs
are capable of a widespread impact on gene regulation
[42].
In the earliest embryonic stages, a single cell zygote trans-
forms to a morula and then to a blastocyst. During this
period the zygote initiates the first cell division and the first
lineage cell undergoes differentiation into the inner cell
mass and the trophectoderm. The processes involved in
these events are complex and regulated by multiple signal-
ling pathways with related biological functions such as cell
division and growth, differentiation, migration, apoptosis,
transformation and polarity. Not surprisingly these func-
tions are tightly interconnected and disruptions in these
networks may lead to abnormal development, disease or
even fatality. Several signalling transduction pathways have
been demonstrated to be involved in the early process of
mammalian embryonic development, including; mitogen-
activated protein kinase (MAPK); phosphatidylinositol 3-
kinase (PI3K)/Akt; Wingless (Wnt)/β-catenin; Notch; bone
morphogenetic protein (BMP)/transforming growth factor
(TGF- β); Hedgehog and Janus-activated kinase (JAK)/-
signal transducer and activator of transcription (STAT).
While these pathways contribute to central events in
development, their stage-specific expression is key to or-
chestrating the correct processes with the correct timing;
this is where miRNAs may have an important role. The
miRNA expression in preimplantation development is a
difficult area to research, particularly in humans and
therefore much of this information is still relatively un-
explored. However miRNA targeting of developmental
pathways does occur early in development and the iden-
tified action of specific miRNAs targeting critical signal-
ling pathways provides evidence of the importance of
these molecules in regulating early development and
assisting in more specified development in separate lin-
eages, and body systems later on (Fig. 1) [47].
There are a large number of miRNAs that have been
confirmed to regulate components in essential develop-
mental pathways. Crosstalk between these signalling
pathways and miRNAs emphasises that miRNAs con-
tribute largely during embryogenesis and early develop-
ment. An example is the Wnt signalling pathway, which
is a major contributor in controlling biological processes
and is extensively researched. There is supportive evi-
dence of miRNAs regulating WNT signalling compo-
nents and being associated with various cancers in the
literature. The signalling pathways critical in early devel-
opment are interwoven with the function of numerous
miRNAs and the affect of aberrant miRNA expression
could have widespread consequences in the development
of a specific organ or body system. Additionally, mice
lacking the essential miRNA-processing enzyme, Dicer,
are embryonically lethal before embryonic day (E) 7.5,
suggesting the roles of the components of the machinery
which produce functional miRNAs, and the miRNAs
themselves, are essential in embryogenesis [48].
miRNA function and links to childhood cancer
development and progression
There are a number of mechanisms that may affect the
miRNA profile in a specific tissue or group of cells. These
events can alter expression in both oncomiRs and tumour
suppressor miRNAs, or on a more global scale, mutations
in components of the miRNA biogenesis pathway may
affect larger groups of miRNAs, and their ability to mediate
repression of target mRNA (Fig. 2.) The let-7 family were
identified early as a group of influential miRNAs. They are
well researched and have been shown to regulate expres-
sion of the RAS oncogenes. Mutations in RAS oncogenes
are present in around 25–30% of all human tumours. In
vitro experiments on a pulmonary adenoma cell lineage in-
dicate that let-7 is able to inhibit cell proliferation through
RAS, which suggests it may play a role as a tumour sup-
pressor [49]. From this investigation, it was determined that
let-7 miRNAs regulate the expression of the RAS protein
and are also able to subsequently affect cell proliferation
rates through the downstream MAPK signalling cascade.
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Although the links between miRNAs and the initiation
and progression of cancer are supported, the area which
remains difficult to interpret and requires further explor-
ation is the exact mechanism by which miRNAs function
to cause downstream effects, or conversely, how miRNA
genes are influenced by other events which may alter the
normal miRNA profile. Often miRNA expression is re-
pressed in cancer compared to normal tissues; contrarily,
there are also some miRNAs overexpressed in cancer [24].
In addition to the deletion and mutation of miRNA
genes, aberrant methylation may cause epigenetic inacti-
vation with subsequent transcriptional suppression. Aber-
rant hypermethylation in mir-9-1, mir-124a, mir-148, mir-
152 and mir-663 was observed in up to 86% of cases in a
cohort of 71 primary breast cancer tissues [50]. Addition-
ally, global or local aberrant methylation of miRNA genes
may also alter the miRNA profile of an individual, subse-
quently providing a vulnerable situation in which normal
Fig. 1 Proposed schematic of early developmental processes linking key signalling pathways and miRNA expression. a The developmental signalling
pathway expression in early stages of development (Carnegie stages 1–9), and the miRNAs demonstrated to regulate these pathways during these
stages. b Carnegie stages 10–17, representing further development and miRNAs ubiquitously expressed in all tissues (except heart and vessels). The
three germ layers are represented and their associated body systems and organs are discussed in a cancer context in this review (kidney; WT, bone;
OS, Neural crest; NB, brain; embryonal brain tumours, liver; HB). Additionally miRNAs associated with each organ/body system are presented
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Fig. 2 (See legend on next page.)
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genetic regulation is lost and the development of cancer
could arise. In relation to this, epigenetic changes of
miRNA promoters, such as alteration of their methylation
status or their histone patterning can also induce changes
in miRNA expression [51]. A number of studies have in-
vestigated the role of methylation and how it may fit in
with disease progression and development. What is im-
portant to note here, and can be applied to other types of
cancer, are the mechanisms by which epigenetic regulation
can occur. Some examples of this include the downregula-
tion of Let-7 family, which has been shown to be down-
regulated through DNA and histone methylation in
gastric cancer, or miR-34b and miR-34c. Or miRNAs can
be downregulated through hypermethylation of the neigh-
bouring CpG islands. These miRNAs are also implicated
in childhood cancers suggesting a common role in onco-
genesis [52] (Table 1). Accumulating evidence suggests
that aberrant methylation of certain miRNA genes may
disrupt a number of key signalling pathways. This could
have major effects in the developmental process, which re-
lies heavily on the maintenance of regulated signalling to
ensure controlled growth, and without which tumourigen-
esis may arise (Fig. 2).
Cancer-related transcriptional control of miRNAs has
also been demonstrated by the observation of transcrip-
tional activation of the miR-17/92 cluster induced by the
MYC oncogene, the upregulation of which modulates
the anti-apoptotic and proliferative actions of E2F1, me-
diating the MYC proliferative effect [13]. Altered miRNA
expression clearly contributes to many cancers through
a variety of different mechanisms, and will continue to
provide insight into cancer onset and progression.
A brief account of childhood solid tumours
In childhood cancers, the pathogenesis of tumours is often
tightly linked with the processes of development such as
organogenesis, tissue growth and maturation [53–58].
This area of research is growing; new resources collating
and examining the links between developmental biology
and oncology are emerging to assist in bringing together
the two research communities to help apply discoveries in
the search for targeted therapies [59]. The processes regu-
lating fetal and postnatal growth and development are
controlled and coordinated by multiple developmental
pathways, such as Hox, WNT, Notch and Hedgehog [47].
Disruption of these strictly regulated pathways through
germline or somatic mutation, or epigenetic or transcrip-
tional dysregulation can transform specific tissues, giving
rise to the early onset of cancer during childhood [30].
The most common types of childhood cancers are leu-
kaemia, brain and central nervous systems tumours and
lymphomas. In addition to these cancers, are the embry-
onal solid tumours of the kidney (Wilms tumour), neural
crest (neuroblastoma), muscle (rhabdomyosarcoma), eye
(retinoblastoma), and the liver (hepatoblastoma). Embry-
onal solid tumours of childhood are more commonly
sporadic than heritable. In some cases they are associ-
ated with various syndromes such as Beckwith-
Wiedemann syndrome (BWS) and in patients with fa-
milial adenomatous polyposis (FAP) [60]. The particular
histological features of the malignant tumours, and the
appearance of corrupted tissue development, are what
characterise this heterogeneous group of tumours.
The role of miRNAs in childhood cancer
It is essential to continue research to build a better under-
standing of the role miRNAs in the development of child-
hood cancers. It is clear that many of these cancers are
tightly associated with irregular events occurring during
development, and what we can learn from the inclusion
and exploration of these vital regulatory elements may be
the key to a deeper understanding of the complex nature
of how childhood cancers arise. Another complex issue in-
volving childhood cancers, where miRNAs may provide
valuable insight, is the development of treatment resist-
ance. It is important to identify aberrant miRNA expres-
sion associated with pathogenesis and also drug resistance,
especially chemoresistance, as this may be critical in pro-
viding lasting and effective treatments for children [61].
The following sections review several types of child-
hood solid tumours, describing common features and
key developmental pathways that have been identified to
contribute to embryogenesis and disease. The following
childhood cancers were selected based on their associ-
ation with a variety of affected organs or body systems,
(e.g. kidneys, liver and brain as well as the sympathetic
nervous system and skeletal system), and because recent
literature has uncovered unique links to miRNAs and
the development of these solid tumours. In addition, the
childhood cancers discussed are those where the etiology
remains unclear and the involvement of miRNAs could
help to explain some of the unique qualities of the
(See figure on previous page.)
Fig. 2 The mechanisms by which alteration of normal miRNA profiles can occur, leading to aberrant miRNA profiles in childhood solid tumours.
Examples of aberrant expression and disrupted miRNA biogenesis are illustrated and are supported by validation in the literature. a Disruptions to
miRNA genes, resulting in upregulation of oncogenic miRNAs or downregulation, or complete loss of expression (tumour suppressor miRNAs). b
Components of the miRNA biogenesis pathway that can be altered, affecting production of mature functioning miRNAs. c Events which alter the
target mRNA and affect the ability of the mature miRNA to bind
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disease and may allow for a better understanding of new
opportunities for targeted therapies. Young children are
most at risk for developing debilitating late effects from
the regimented chemotherapy courses. Through know-
ledge gained from these studies, we may be able to make
better predictions about prognosis.
Embryonal tumours of the brain
A number of studies in recent times have indicated the
frequent involvement of miRNAs in the progression and
development of childhood brain tumours, and that this
tumour has unique characteristics among rare tumour
types. Brain tumours are among the most common
cancers in children. The different tumour types and clas-
sifcations are generally based on cell structure, compos-
ition, growth rate of the tumour and a range of further
characteristics. Central nervous system primitive neuro-
ectodermal brain tumours (CNS-PNETs) are a heteroge-
neous group of CNS neoplasms. These tumours are
composed of poorly differentiated neuroepithelial cells
and, some variants are associated with aggressive clinical
behaviour and poor outcome.
Chromosome 19q13.41 contains the largest human
miRNA gene cluster (chromosome 19 miRNA cluster,
C19MC); the miRNAs comprising this cluster have been
identified as oncogenic [62]. C19MC may drive oncogenic
processes in part by facilitating maintenance and transform-
ation of a very early neural compartment [63, 64]. A
particularly aggressive group of CNS-PNET tumours dem-
onstrated C19MC amplification with high LIN28 expres-
sion. In addition, recent identification of Tweety family
member 1 (TTYH1):C19MC gene fusions in embryonal
Table 1 Summary of miRNAs that are consistently downregulated in different childhood solid tumours
miRNA/miRNA cluster Childhood cancer
type*
Comments Ref
miR-16 OS Differentially expressed compared to healthy bone tissue [103]
miR-29b OS Differentially expressed compared to healthy bone tissue [103]






NB, OS Targets MYCN, identified as tumour suppressors, often
found in 1p deletion in MNA NB tumours, targeted by p53
[79], [82],
[84], [97–101]
miR-451 OS Higher expression in pre-treatment samples, corresponded
with positive response to chemotherapy
[103]
miR-15b OS Higher expression in pre-treatment samples, corresponded
with positive response to chemotherapy
[103]
miR-125b-1-3p NB Lower expression may be associated with chemoresistence [86]
miR-199a-3p OS Differentially expressed in OS cell lines, regulation of
proliferation in osteoblasts, acts as tumour suppressor
[96]
miR-127-3p OS Differentially expressed in OS cell lines, regulation of
proliferation in osteoblasts, acts as tumour suppressor
[96]
miR-370 OS Differentially expressed in OS cell lines, regulation of




Let-7a, Let-7b, Let-7c, Let-7d,
Let-7e, Let-7f, Let-7 g, Let-7i,
miR-98
WT Impaired expression observed due to DICER1 and DROSHA
mutations, regulators of MYCN and LIN28
[28] [113]
miR-195 HB Differentially expressed in fetal subtype compared to
surrounding normal liver tissue
[121]
miR-210 HB Differentially expressed in fetal subtype compared to
surrounding normal liver tissue
[121]
miR-214 HB Differentially expressed in fetal subtype compared to
surrounding normal liver tissue
[121]
miR-124 PA Differentially expressed in PA tumours compared to
normal brain tissue, targets putative oncogenes, enriched
in brain tissue
[66], [67]
miR-218 MB Low expression observed, targets include pathways involved in
cell cycle, metabolism and motility, CDK6 is target of interest
(upregulates cell cycle progression and blocks differentiation)
[71], [72]
miR-497 NB Targets key cell cycle regulator WEE1. Low levels seen in high risk
MNA tumours which also display high levels of WEE1. It is a
candidate tumour suppressor and may be useful as a therapeutic target.
[85]
*NB neuroblastoma, MB medulloblastoma, OS osteosarcoma, WT Wilms Tumour, HB hepatoblastoma, PA pediatric pilocystic astrocytoma
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tumours with multi-layered rosettes (ETMRs) have been
identified and observed to be associated with very high ex-
pression of specific miRNAs. ETMRs are a rare and deadly
form of paediatric brain tumours, and are characterized by
high levels of amplification of C19MC. ETMRs, cell lines
and xenografts all demonstrated specific DNA methylation
signatures distinct from other tumours and normal tissues,
very high overexpression of a previously uncharacterized
isoform of DNMT3B, which originates from an alternative
promoter, and which is interestingly only active in the first
weeks of neural tube development. This research uncovers
a potential oncogenic re-activation of an early developmen-
tal signalling program in ETMR via an epigenetic alteration
mediated by the brain specific DNMT3B isoform, which
has a known embryonic origin [65].
Pediatric pilocystic astrocytoma (PA) is a Word Health
Organisation grade I glioma. It is a brain tumour, which
often arises in the cerebellum or close to the brain-
stem in the hypothalamic region or the optic chiasm.
However it is possible for it to occur in any location
where astrocytes are present (cerebral hemispheres, and
the spinal cord). While often these tumours are slow
growing and benign, the neoplasms can be cystic and
grow very large, causing multiple problems due to the
increased intracranial pressure. miRNA profiling has
been performed in a group of 43 PA tumours and 5
non-neoplastic brain controls. Differentially expressed
miRNAs were identified between PA and normal brain
tissue; 13 miRNAs were underexpressed in PA and 20
were over expressed compared to normal brain tis-
sue (Table 1). An example of the importance of a few of
these differentially expressed miRNAs is miR-124, which
was underexpressed in PA tumours, confirming previous
findings. miR-124 targets putative oncogenes, is enriched
in brain tissue, and is also found to be downregulated in
glioblastomas. miR-124 also has been shown to nega-
tively affect glioblastoma proliferation and migration in
vitro [66, 67]. Additionally, upregulation of miR-21 was
shown in these tumours and elevation of this miRNA
has also been seen in other tumour types, compared
with normal tissues (Table 2). An important target of
miR-21 is PTEN, a critical suppressor of the PI3K/Akt/
mTOR pathway. Previously PTEN loss had been fre-
quently identified in high-grade gliomas, and decreased
levels had been shown in PAs with particularly aggres-
sive histological features. An overall observation of miR-
NAs in PA is that there are sets of miRNAs
underexpressed compared to controls, and alongside this
there is increased expression and protein levels of puta-
tive oncogenes which may be vital in understanding the
biology of PA [68, 69].
Ependymal tumours (ET) are the third most common
group of brain tumours in children. These tumours com-
prise four entities; the most common are grade II and
grade III, most of which are located in the posterior fossa,
with infiltration into vital brain structures. Due to the dif-
ficult location of these tumours surgical resection is highly
limited. Additionally there are currently no effective prog-
nostic features aside from how accessible they are to surgi-
cal intervention. Childhood ependymomas usually don’t
have genomic imbalances, further making it difficult to es-
tablish molecular prognostic features. Recently, however,
three miRNAs were demonstrated to differentiate between
grade II and III ependymomas. These include miR-17–5p,
miR-19a–3p and miR-106b–5p, and the expression of
these miRNAs was also significantly correlated with EZH2
expression (a suggested marker for PFA ependymomas).
Survival analysis indicated overall and event free survivals
were reduced with higher expression levels of miR-17–5p
[70].
Medulloblastomas (MBs) are a common brain tumour
in children, thought to originate in cerebellar granule
neuron progenitors, which have failed to undergo nor-
mal cell cycle exit and differentiation. In MB miR-218
expression is downregulated, and low expression of this
miRNA has been identified in other cancer types. In
addition, reduced expression has been observed in gli-
oma cells [71] (Table 1). Previous research has identified
multiple targets of miR-218 that control pathways in-
volved with the cell cycle, cell metabolism and motility.
Of those identified, CDK6 is of interest as it has previ-
ously been identified as an adverse prognostic marker in
MB because of its role in upregulating cell cycle progres-
sion and blocking differentiation [72]. The miR-17-92
cluster is also implicated in MB. Mouse MB models have
demonstrated overexpression of several members of the
miR-17-92 cluster, three of which, (miR-19a, miR-20,
miR-92), were also overexpressed in human MBs with a
constitutively activated Sonic Hedgehog signaling path-
way, and not in other forms of the disease (Table 2). To
explore whether the miR-17-92 cluster could be promot-
ing MB formation, the expression of these miRNAs was
enforced in granule neuron progenitors isolated from
cerebella of postnatal day six mouse models (lnk4c−/−;
ptch1+/−). These mice formed MBs in orthotopic trans-
plants with complete penetrance, but in similarly engi-
neered cells from lnk4−/−; p53−/− mice there was no
MB formation. These findings point toward a possible
functional connection between the miR-17-92 cluster,
the Sonic Hedgehog signaling pathway, and the develop-
ment of MBs in both mice and humans [73].
Neuroblastoma
Neuroblastoma (NB) is an extracranial solid childhood
tumour, and is the most common cancer in infants. The
cancer is a neuroendocrine tumour, stemming from neural
crest elements of the sympathetic nervous system; it is
an ectodermally derived tumour, which reflects its
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developmentally derived origin [59]. While it frequently
originates in one of the adrenal glands, it can also develop
in nerve tissues in the neck, chest, abdomen or pelvis [74].
It is a unique and interesting cancer, as it is one of the few
malignancies that can demonstrate spontaneous regres-
sion from an undifferentiated state to a benign cellular
appearance; additionally, there is a large amount of het-
erogeneity observed in these tumours [75].
Recent work in this area suggests the dysregulation of
miRNAs may play an important role in the pathogenesis
of NB. For instance, the miR-17-5p-92 cluster of miRNAs,
(miR-17-5p, miR-18a, miR-19a, miR-20a and miR-92), is
found to be expressed at higher levels in NB cells lines
exhibiting overexpression of MYCN [76]. Tumours with
amplification of the MYCN transcription factor and/or
loss of the distal chromosome 1p and gain of 17q are a
Table 2 Summary of miRNAs that are consistently upregulated in different childhood solid tumours
miRNA/miRNA cluster Childhood cancer
type*
Comments Ref
miR-27a OS Higher expression in pre-treatment samples
characterized metastatic disease
[103]
miR-188-5p NB Higher expression may be associated with
chemoresistance
[86]
miR-501-5p NB Higher expression may be associated with
chemoresistance
[86]
miR-135b OS Differentially expressed in OS cell line compared
to normal osteoblast cell line, association with
osteoblast differentiation
[91–95]
miR-150 OS Differentially expressed in OS cell line compared
to normal osteoblast cell line
[91]
miR-542-5p OS Differentially expressed in OS cell line compared
to normal osteoblast cell line
[91]
miR-652 OS Differentially expressed in OS cell line compared
to normal osteoblast cell line
[91]
miR-181a OS Differentially expressed compared to healthy
bone tissue
[103]
miR-181b OS Differentially expressed compared to healthy
bone tissue
[103]
miR-181c OS Differentially expressed compared to healthy
bone tissue
[103]
miR-492 HB Elevated levels co-expressed with KRT19, a potential
biomarker for metastatic HB and poor prognosis
[120]
miR-222 HB Low relative expression associated with increased
overall survival of HB
[121]
miR-224 HB Low relative expression associated with increased
overall survival of HB
[121]
miR-221 HB Differentially expressed in fetal subtype compared
to surrounding normal liver tissue
[121]
miR-483-3p HB High overexpression in tumour specific serum able
to diagnose liver mass
[123]
miR-205-5p HB High overexpression in tumour specific serum able
to diagnose liver mass
[123]
C19MC miR-512-5p, miR-512-3p, miR-1323, miR-498,
miR-520e, miR-515-5p, miR-515-3p, miR-519e-5p,
miR-miR-519e-3p, miR-520f, miR-1283, miR-520a-5p,
miR-520a-3p, miR-526b-5p, miR-526b-3p, miR-519b-5p,
miR-519b-3p, miR-525-5p, miR-525-3p, miR-523-5p,
miR-523-3p, miR-518f-5p, miR-518f-3p, miR-520b
CNS-PNET ETMR C19MC amplification seen in both CNS-PNET and
ETMRs, miRNA members are considered oncogenic
and may maintain transformation of a very early
neural compartment.
In CNS-PNET C19MC amplification is observed with
high LIN28 expression.
In ETMRs TTYH1:C19MC gene fusions are observed




miR-106b ET Associated with the progression of ET from
grade II to grade III, potential prognostic marker
[70]
*NB neuroblastoma, OS-osteosarcoma, HB hepatoblastoma, CNS PNET-central nervous system primitive neuro-ectodermal brain tumour, EMTR embryonal tumours
with multi-layered rosettes, and ET ependymal tumour
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major genetic subtype of metastatic NB that has a particu-
larly poor prognosis (known as MNA). It has also been
demonstrated that MYCN proteins c-Myc/N-Myc can
bind directly to the promoter of the miR-17-5p-92 cluster,
initiating transcription and resulting in the up-regulation
of this group of miRNAs from a single transcription unit
[77, 78]. A poor prognosis and therapy resistance is associ-
ated with MYCN amplified NBs. However, previous
research has shown that therapy resistant NB can be
abolished in vivo using antagomir-17-5p [76].
Components within the miRNA biogenesis pathway have
also been implicated in NB, which globally affects miRNA
expression. A group of 66 tumours were assessed for a
panel of 162 miRNAs using quantitative PCR and low ex-
pression of DICER and DROSHA were identified in high-
risk tumours. The low expression subsequently accounted
for the overall global reduction of miRNA expression ob-
served in the advanced disease state and correlated with a
poor outcome for these patients [26]. A global reduction of
miRNA expression can be detrimental, and conversely the
presence of some miRNAs has been attributed to more
positive outcomes, such as the tumour suppressor miR-34a,
which is also a critical component of the p53 network [79,
80]. This miRNA has anti-proliferative effects and has been
found to target MYCN. miR-34a is located on chromosome
1 and it is not surprising that lower levels are expressed in
tumours with/or due to a 1p deletion [81]. This type of de-
letion is found most often in the MNA type of tumours; a
functionally active miR-34a would help to negate the ill ef-
fects of the amplification of MYCN. miR-34a is also in-
volved in the regulation of other genes associated with cell
proliferation and apoptosis such as E2F3, BCL2, CCND1,
and CDK6 [82, 83]. Since miR-34a plays many roles in con-
trolling and regulating growth, it is obvious disruption of
the function of this miRNA would be deleterious and could
lead to unrestricted growth leading to cancer development,
and indeed miR-34a has been described previously as a
tumour suppressor [79, 84]. Another miRNA that has been
reported as a potential tumour suppressor is miR-497; this
is due to its action in targeting the key cell cycle regulator
WEE1. Expression of miR-497 in MNA tumours is signifi-
cantly lower than other tumour types, and high WEE1
levels (low miR-497) are significantly associated with poor
overall survival and event free survival in NB (Table 1).
Additionally, overexpression of miR-497 reduces cell viabil-
ity and increases apoptosis in MNA cells, and in particular
was found to be compatible with an enhanced response to
cisplatin. The discovery of the complexity involved in
miRNA control has begun to uncover new and promising
therapeutic targets for high-risk NB patients [85].
Another common issue seen in childhood solid tumours
is chemotherapy resistance; one study investigated drug
resistance and expression of miRNAs, and identified sev-
eral miRNAs of interest in NB chemoresistance models.
Their results confirmed an up-regulation of the expression
of miR-188-5p in all three of the chemoresistance models
examined; miR-501-5p was found up-regulated, and miR-
125b-1 was down-regulated in two of the models [86].
These types of investigations are valuable in identifying
good miRNA candidates for in-depth exploration to look
for novel drug development and perhaps RNAi based
therapies for those individuals who are not responding to
chemotherapy and may have more aggressive tumour
types [87, 88].
Osteosarcoma
Osteosarcoma (OS) is an aggressive malignant neoplasm
of the bone that originates in primitive transformed
mesenchymal cells [89]. This cancer begins in osteo-
blasts responsible for forming new bone and is common
in adolescents. Bone formation is a dynamic process; or-
chestrating osteoblast differentiation, which requires
precise mechanisms of control, and is particularly crit-
ical for both development and growth. OSs tend to
occur at the sites of bone growth, and the proliferation
occurring at these locations may make the osteoblastic
cells more susceptible to acquiring mutations, or other
events, which may induce the transformation of cells
[90]. Therefore, often the ends of long bones (arms and
legs) are affected, although formation in the knee is also
a common event.
The molecular etiology of OS remains elusive; miR-
NAs have been investigated in association with many
diseases due to their properties that may allow for wide-
spread effects on development and disease progression.
In prior investigations four miRNAs were found to be
differentially expressed in OS cell lines compared to nor-
mal human osteoblast cell lines [91]. The miRNAs that
were overexpressed in the OS cell lines included, miR-
135b, which has previously been implicated in cancer
and is associated with osteoblast differentiation, miR-
150, miR-542-5p and miR-652 [92–95]. Several miRNAs
have been identified that may act as tumour suppressors
in OS and are additionally found to be down-regulated
in OS cell lines. These miRNAs, (miR-199a-3p, miR-
127-3p and miR-370), assist with the suppression of
oncogenic and anti-apoptotic proteins and also play a
role in regulating proliferation of the osteoblasts [96]. As
with NB, the miR-34 family is again highlighted as an
important regulator of growth signals and acts as a
tumour suppressor miRNA. These miRNAs are targeted
by p53 and play a very important part of the tumour
suppressor pathway [82, 97–102].
In a recent investigation, a miRNA signature reflecting
the pathogenesis of OS was described using surgically
procured samples from human patients [103]. These
samples highly expressed miR-181a, miR-181b and miR-
181c and also showed reduced expression of miR-16,
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miR-29b and miR-142-5p. However, it is noteworthy this
study also identified valuable pre-treatment biomarkers
of metastasis and indicators of responsiveness to ther-
apy. The biomarkers and indicators of metastatic devel-
opment risk included a higher expression of miR-27a
and miR-181c-3p in the pre-treatment samples. This
characterised patients who went on to develop metastas-
tic lesions. Furthermore, higher expression of miR-451
and miR-15b in pre-treatment samples correlated with
positive responses to chemotherapy [103].
Wilms tumour
Wilms tumour (WT), or nephroblastoma is a solid
tumour occurring in the kidneys of children. Embryonal
renal neoplasms are thought to develop in nephrogenic
rests (NRs) with morphological and molecular analogies
to kidney development. Most commonly WTs are unilat-
eral with a single tumour affecting the kidney. However
multiple tumours can arise in one of the kidneys, or the
cancer may occur bilaterally in both kidneys [104, 105].
In WT relatively few driver genes have been identified
[106]. Recently both Sanger sequencing and whole ex-
ome sequencing have provided the means to identify
mutations in critical elements of the miRNA processing
machinery in WT patients. Several recent studies have
uncovered miRNA biogenesis disruptions in WT, which
provides an excellent starting point for research in this
area [27, 28, 107]. Rakheja and colleagues investigated
the presence of these potential mutations in 44 WT sam-
ples using whole-exome sequencing [28]. In addition to
identifying novel mutations in MYCN, SMARCA4 and
ARID1A, missense mutations were discovered in the
miRNA processing enzymes DROSHA and DICER1. Fur-
ther examination of tumour miRNA expression using in
vitro processing assays and genomic editing of cell lines
demonstrated that these mutations in DROSHA and
DICER1 greatly influence miRNA processing and likely
cause down regulation in mature miRNAs, which gener-
ate an altered miRNA expression profile in these WT
patients. Further, there were distinct mechanisms also
identified; DICER1 RNase IIIB mutations preferentially
affected the processing of miRNAs derived from the 5’
arm of pre-miRNA hairpins. Conversely DROSHA
RNase IIIB mutations were found to cause global inhib-
ition of miRNA biogenesis through a dominant-negative
mechanism. Mutations in these enzymes also impaired
the expression of tumour suppressor miRNAs such as
the let-7 family; this is an important regulator of genes
such as MYCN, LIN28 as well as other previously identi-
fied WT oncogenes [28]. Downregulation of certain
miRNAs in WT were also observed to have a major
affect on critical pathways that are involved in kidney
development, such as, TGF-β. For example Activin A re-
ceptor type 2B (ACVR2B), an important component of
the TGF-β pathway, is often highly expressed in renal
neoplasms; several miRNAs have been noted as down-
regulated and have been confirmed to directly target this
gene (Table 1). This investigation was the first to impli-
cate the TGF-β pathway in the pathogenesis of WT
[108].
A number of up regulated miRNAs were also identi-
fied in WT; up-regulation of miR-17-5p, miR-18a, miR-
19b, miR-92 and miR-20a was reported in WT compared
to other kidney tumours or normal kidney tissues [109].
This is of interest, because the cluster (miR-17-5p-92)
was also identified as being up-regulated in the subtype
of NB known as MNA [76] (Table 3). As mentioned,
these miRNAs are thought to contribute to tumour pro-
gression and metastasis in the later stages of the cancer
[103, 110]. Other miRNAs found to be upregulated in
WT have been investigated for being able to distinguish
the different subtypes of WT and for giving an indication
on severity of disease, or for influencing important fac-
tors such as endothelial to mesenchymal transitions
(EMT) and chemosensitivity [111]. Another mechanism
recently recognised in the development of WT is the ab-
errant regulation of miRNA Let-7 through overexpres-
sion of LIN28 [112]. Let-7 is a direct target of LIN28,
and it is a potent regulator of stem cell self-renewal and
differentiation. A murine model has shown that directed
overexpression of both LIN28A and LIN28B in the renal
lineage results in the formation of WTs [113]. Further
investigation of LIN28 expression in mutant mice re-
vealed that terminal differentiation only occurred in
nephron progenitor cells after LIN28 had been com-
pletely withdrawn. It is plausible that the overexpression
of LIN28 may cause an imbalance in proliferation and
differentiation in these specific cells, rather than a
complete blockage of differentiation, resulting in the for-
mation of these types of tumours [113, 114].
Hepatoblastoma
Hepatoblastoma (HB) is a relatively rare disease, al-
though it is the most common childhood liver cancer. It
is often diagnosed as an asymptomatic abdominal mass
[115]. The most commonly affected age group are in-
fants between six months and three years of age. The
majority of HB cases are sporadic. However, HB may
occur in conjunction with a developmental syndrome
such as Beckwith-Wiedemann Syndrome (BWS) and Fa-
milial Adenomatous Polyposis (FAP) [116, 117].
Since HB is a rare cancer, research is challenging and
often relies on formalin fixed paraffin embedded (FFPE)
samples, which are known to provide obstacles in the ex-
traction of total RNA due to degradation. However, recent
research has demonstrated miRNA expression is relatively
stable and well preserved in these valuable archival samples
which is an important factor for future research in this field
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[118, 119]. Previous studies provided evidence for a few
prognostic miRNAs associated with HB, such as miR-492,
which is a potential biomarker in metastatic HB. Overex-
pression of pleiomorphic adenoma gene 1 (PLAG1) has
been characterised in HB, and has been demonstrated
through RNA interference analysis combined with
miRNA arrays to strongly influence miR-492. Add-
itionally, it was revealed that miR-492 could originate
from the coding sequence of the HB marker gene
keratin 19 (KRT19). Significantly elevated levels of co-
expressed KRT19 and miR-492 were identified in meta-
static HB tumour samples [120]. This is of interest as
metastatic HB is often associated with poor prognosis. In-
deed, miR-492 and its associated targets may provide bio-
markers or inform on targeted therapies [120].
Other potential prognostic miRNAs have been identi-
fied in a recent study, which showed that histological
subtypes of a group of 20 tumour samples did not cor-
relate with survival. However this investigation did
identify that the levels of several miRNAs were inde-
pendently prognostic for HB with significantly increased
overall survival. These miRNAs included the high rela-
tive expression of miR-21 and low relative expression of
miR-222 and miR-224 [121] (Tables 2 and 3). In a recent
study miR-21 was examined for its potential role as a
diagnostic/prognostic indicator in peripheral blood
where it has been reported to be relatively stable within
protective exosomes or nanovesicles. Exosomes, which
can be released in large amounts from tumour cells due
to a hypoxic environment and other internal changes,
are of interest because a blood sample is a less invasive
method for diagnosis and prognosis for the patient.
Blood samples were prepared retrospectively in 32 Chin-
ese hepatoblastoma patients and healthy controls; the
blood samples were separated to isolate RNA directly
from the exosomes present in the sample (which precipi-
tate at the bottom), while also preparing exosome-
depleted samples (using the supernatant of the same
sample). The concentration of miR-21 in the exosomes
prepared from blood of HB patients was significantly
higher than in exosome-depleted supernatants and
whole plasma. The expression of miR-21 detected in HB
children was significantly higher in both the plasma and
exosomes when compared to controls. Additionally, exo-
somal miR-21 is not only an independent predictor of
event-free survival for patients, it also was more accurate
in diagnosing HB than alpha-fetoprotein levels (AFP),
the traditional means of HB diagnosis [122]. There were
also miRNAs identified with unique expression levels in
both fetal and embryonal subtypes in comparison with
surrounding non-tumorous liver tissues. In the fetal sub-
type of samples, there was a lower expression compared
Table 3 Summary of miRNAs that are either up or down regulated or contains conflicting evidence of expression in childhood solid
tumours
miRNA/miRNA cluster Childhood cancer type* Comments Ref
miR-17-92 cluster miR-17-5p, miR-18a,
miR-19a, miR-19b,
miR-20a, miR-92
NB, WT, MB, ET (upregulated) c-Myc/n-Myc bind to increase expression in
MYCN amplified NB
[70, 76–78, 109, 121]
HB (downregulated) Upregulation in WT compared to other kidney
tumours or normal tissue
Lower expression of miR-17-5p in fetal subtype
of HB compared to surrounding non-tumourous
liver tissue
Overexpressed in mouse MB models and human
MBs (some with constitutively activated Sonic
Hedgehog signalling)
High levels of expression of miR-17-5p and
miR-19a-3p associate with grade III (advancement)
in ET
miR-21 HB (Downregulated) High relative expression associated with increased
overall survival of HB
[121]
PA (upregulated) Upregulation seen in PA with more aggressive
histological features, an important target is PTEN
miR-122-5p HB (upregulated,
dowregulated)
miR-21 was detected in higher levels in HB patients
in both the plasma and exosomes compared to
control patients.
[25, 122–124]
Low expression of miR-122-5p is seen in the embryonal
subtype of HB. Serum miRNA profiles of HB patients
indicated high expression of miR-122-5p and could be
used in a panel to perform a non-invasive differential
diagnosis of liver mass.
*NBneuroblastoma, MBmedulloblastoma, WT Wilms’ Tumour, HB hepatoblastoma, PA pediatric pilocystic astrocytoma, and ET ependymal tumour
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to surrounding normal liver tissue in miRNAs miR-17-
5p, miR-195, miR-210 and miR-214, while higher expres-
sion was observed in miR-221 (Tables 1, 2 and 3). In the
embryonal subtype of HB a lower expression of miR-
122-5p was demonstrated. Loss of miR-122-5p is also
frequent in hepatocellular carcinoma (HCC) and has
been correlated with migration, invasion, and in vivo
tumorigenesis. miR-122-5p is also considered a differen-
tiation marker for hepatocytes. Lower miR-122-5p ex-
pression levels indicated in the embryonal subtype is in
agreement with the lower degree of differentiation found
in early embryonal development. In a recent comprehen-
sive investigation of 33 different types of childhood solid
tumours and 20 control cases, serum miRNA profiles
were examined. Four HB samples were included in this
group of tumours and tumour specific serum miRNA
profiles were determined for each specific tumour type.
Using the panel of miRNAs identified for HB, (high
overexpression of miR-483-3p, miR-205-5p, and miR-
122-5p), a non-invasive differential diagnosis of a liver
mass could be performed when compared to tumour
mixed samples of neuroblastomas (MYCN-amplified and
others) [25]. It is of interest that contradicting results
from two studies identified miR-122-5p as being of
interest, except at opposite ends of the spectrum, (one
observing lower relative expression and the other stating
the miRNA to be in the top ten of the highest relative
overexpression) (Table 3). It is important to acknowledge
that in serum miRNA profiling investigations only four
HB samples were investigated, and in addition the au-
thors pointed out that miR-122-5p was found in in-
creased levels in non-HB samples in this study, such as
in pancreatic pleiomorphic rhadomyosarcoma (RMS)
presenting with obstructive jaundice [25]. Serum levels
of miR-122-5p were increased, while the expression of
miR-122-5p was reduced in liver tissue, which could be
due to passive miRNA drainage from tumour cells, as
has been observed in other tumours [123]. Expression of
miR-122-5p has been identified as a non-specific marker
of liver damage, and is increased in the serum of jaun-
diced patients [124]. These studies highlight the import-
ance of identifying miRNA profiles (in tumour tissue
and in serum), and shows that there may be specific
miRNAs with unique roles in various types of childhood
solid tumours.
Conclusions
The role of miRNAs in the regulation of critical signalling
pathways such as Wnt/β-catenin, Notch, and TGFβ/BMP,
has emerged as an important area in the exploration of
childhood cancer development. Childhood solid tumours
often display heterogeneous embryonic features, pointing
to an early origin of tumourigenesis. While research
into miRNA expression at very early stages of embryonic
development (preimplantation) is largely unexplored at this
stage, there is evidence that miRNAs regulate key compo-
nents of several developmental pathways following these
stages, and that expression of miRNAs directs development
and differentiation of specific cells and tissues, which be-
comes more complex as the embryo continues to develop
(Fig. 1). If disruptions occur to the network of regulatory
connections between miRNAs and developmental signal-
ling pathways, then this may lead to incorrect maintenance
of signalling, promoting an environment where prolifera-
tion is enhanced, and cells are able to evade apoptosis, or
remain in a more pluripotent state. In this instance the nor-
mal growth regulatory processes have lost control, or are
mis-timed, and therefore may initiate tumour growth.
In the childhood tumour types discussed above, there
are miRNAs (or clusters) that are clearly implicated in
more than one type of tumour (Tables 1, 2 and 3). Iden-
tifying key miRNAs, which act as tumour suppressors,
or as oncomiRs, is already a growing area of interest, but
the discovery of a common miRNA regulated mechan-
ism throughout all childhood solid tumours would be
immensely valuable in identifying new targeted therapies
[125]. The miR-17-92 cluster is implicated in several
childhood solid tumours and is highlighted in this review
in NB, WT, HB and MB; it is a well-researched topic
and is known to be vital in early development [126].
Members of the cluster have been found to be ubiqui-
tously expressed in all tissues (except the heart and
blood vessels) in early chick embryos, which would sug-
gest these miRNAs play a role in regulating baseline pro-
cesses that are critical in many different cell and tissue
types. The shared expression of this group of miRNAs is
an interesting phenomenon and could potentially hold
promising targets for the development of new therapies
in treating childhood solid tumours [127]. Another set
of miRNAs worth further investigation, which are impli-
cated in several paediatric tumours, is the C19MC
group (Table 2). The miRNAs in this cluster are also
thought to be oncogenic, and appear to be closely linked
to early neural tube development, and may act in pro-
moting transformation and maintenance of these early
proliferative cell types. The C19MC group appears to be
especially critical in the formation of embryonal brain
tumours, particularly those with aggressive histology. It
would be worth determining if this cluster is active in
other childhood solid tumours, or if it is brain specific.
It is critical to uncover the mechanisms by which aber-
rant developmental signalling occurs and how these pro-
cesses may be manipulated to regress into a more
regulated path without causing additional disruption in
embryonic development. Since these events may occur
very early, it has thus far been challenging to study
miRNA expression in embryo preimplantation. However,
miRNA expression in the stages following implantation,
Leichter et al. Molecular Cancer  (2017) 16:15 Page 13 of 17
at the beginning of embryonic development, is vital and
has been widely researched. The discovery of miRNAs
themselves were uncovered in the investigation of devel-
opmental timing in C. elegans [1].
While it is hopeful that elucidation of how miRNAs
contribute to the formation of solid tumours can help
revolutionise the approach to treating patients, it adds yet
another layer of complexity to an already entangled web
of interactions occurring both at the genetic and epigen-
etic level. Currently there are over 2,500 mature human
miRNA products identified in humans [128]. Given that
each miRNA is able to target tens or even hundreds of dif-
ferent genes, the development of targeted therapies will be
difficult, and due to the nature of miRNAs and their abil-
ity to be “flexible” in base pair complementarity to their
targets, it seems that if specific miRNAs were targeted
therapeutically, it might give rise to a compensatory effect
from other related miRNAs [129]. In addition, often mem-
bers of the same family of miRNAs tend to target shared
transcripts; this is due to the similarities in the seed re-
gion. At the current time communities of miRNAs are still
being discovered that share a significant proportion of tar-
get genes through co-expression analyses, and therefore
there is still much to be uncovered about the integrated
functional categories of different miRNAs and how they
interact [130]. Ideally, uncovering the initiating events in
miRNA expression, (when the first miRNAs are expressed
in development and how this takes place), would help in-
form on how disruptions may occur and allow researchers
to strive toward better classification of the contributions
of miRNAs in embryonal solid tumours. However, it re-
mains that the number of investigations in the different
types of childhood solid tumours are still relatively few;
translation of this research into miRNAs, or their up-
stream counterparts is poised to expand to other solid tu-
mours. This will assist in uncovering highly valuable links
between different kinds of tumours. In the future these
discoveries may form the basis to develop a type of shared
network of miRNAs or specific mutations in biogenesis
pathway components that could help in the customisation
of current therapeutic treatments, or even the generation
of new, targeted therapies.
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